South Dakota State University is partnering with Boehringer Ingelheim Vetmedica to develop a vaccine to protect pigs against a deadly form of E. coli.
The research and resulting technology was developed by associate professor Weiping Zhang and professor David Francis in SDSU's Veterinary and Biomedical Sciences Department.
Boehringer Ingelheim Vetmedica is helping SDSU take it to market.
The technology also has possible applications in human health, for which Zhang is conducting research projects funded by the National Institute of Health and the Bill & Melinda Gates Foundation, and is pursuing and developing a patent position in collaboration with the TTO.
SDSU's Technology Transfer Office works with SDSU scientists to protect the intellectual property they develop through their research. The office also works with private industry to bring those SDSU discoveries out of the laboratory and into the marketplace where they can provide practical solutions to the problems people face.
The research is one of the ongoing projects in SDSU's Center for Infectious Disease Research and Vaccinology, which looks for new ways to diagnose and treat infectious disease in humans and domestic animals.